Duchenne Muscular Dystrophy: Causes, Symptoms, and Emerging Cell Therapies
- Duchenne muscular dystrophy is a severe genetic neuromuscular disease caused by the absence of functional dystrophin, according to medical research and public health documentation.
- Duchenne muscular dystrophy affects approximately 1 in 5,000 to 6,000 boys, according to data from a review published in PMC.
- The first symptoms of Duchenne muscular dystrophy are usually noticed by parents when children are between one and three years old.
Duchenne muscular dystrophy is a severe genetic neuromuscular disease caused by the absence of functional dystrophin, according to medical research and public health documentation. The condition typically is diagnosed in boys during early childhood and leads to progressive muscle degeneration, resulting in the loss of ambulation, respiratory insufficiency requiring non-invasive ventilation, cardiomyopathy, and premature death in early adulthood. Glucocorticoids remain the cornerstone of pharmacological treatment, as detailed in established clinical guidance.
Understanding the Pathophysiology of DMD
Duchenne muscular dystrophy affects approximately 1 in 5,000 to 6,000 boys, according to data from a review published in PMC. The primary driver of the rapid and irreversible progression of the disease is the absence of functional dystrophin, which is a 427 kDa actin-binding protein and a crucial component of the dystrophin-glycoprotein complex. More than 7,000 patient-specific mutations have been identified in the DMD gene, which stands as the largest human gene, containing 79 exons and approximately 2.4 million base pairs. The absence of dystrophin disrupts the connection between the intracellular cytoskeleton and the extracellular matrix by linking F-actin and the dystrophin-glycoprotein complex, which normally functions as a shock absorber and force transducer in muscle and cardiomyocytes. This disruption causes increased sarcolemmal damage during muscle contractions and interferes with nitric oxide synthesis and calcium entry homeostasis. Beyond skeletal muscle, dystrophin is also expressed in cardiomyocytes and smooth muscle cells, meaning the lack of the protein profoundly impacts multiple organ systems.
Clinical Signs and Disease Progression
The first symptoms of Duchenne muscular dystrophy are usually noticed by parents when children are between one and three years old. Clinical signs manifest as a struggle to sit down, stand up, walk, jump, climb stairs, and run. Affected young boys frequently display calf muscle enlargement, poor head control, muscle pain, and general clumsiness. A characteristic clinical feature of the condition is Gowers’ sign, where weakness in the proximal muscles forces a child to use their hands to rise from a lying position. Between the ages of 8 and 14, patients gradually lose ambulation due to progressive muscle atrophy and become dependent on assistive devices.
Emerging Cell Therapy Strategies and Current Challenges
Because Duchenne muscular dystrophy remains an incurable disease, researchers are actively investigating cell therapy as a potential treatment option, although it has not yet been clinically established, according to a review published on August 22, 2026, in The Lancet. Investigative strategies include muscle satellite cells, mesoangioblasts which are vessel-associated multipotent stem cells, and induced pluripotent stem cell-derived muscle cells designed to restore dystrophin expression and regenerate damaged tissue. Despite these investigative advancements, each approach faces significant limitations that require rigorous evaluation. According to scientific literature, these barriers include poor cell engraftment, low delivery efficiency, and the risk of immune rejection. Furthermore, long-term safety, the possibility of tumorigenicity, and off-target effects must be carefully assessed. Cardiomyocytes differentiated from induced pluripotent stem cells hold specific potential for addressing cardiomyopathy, which represents the major cause of death for patients with Duchenne muscular dystrophy. At the same time, researchers warn that several interventions using cells with claimed stem cell potential have emerged, raising both scientific and ethical concerns.